U.S. License Holder:
Mylan / Biocon
Date of License:
April-10-2025
Last Update:
Apr-30-2025
FDA-Approved Indications
JOBEVNE (bevacizumab-nwgd) is a vascular endothelial growth factor inhibitor indicated for the treatment of:
Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment;
Metastatic colorectal cancer, in combination with fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen;
Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment;
Recurrent glioblastoma in adults;
Metastatic renal cell carcinoma with interferon alfa;
Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan;
Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Jobevne as a single agent, for stage III or IV disease following initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens; in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Jobevne as a single agent, for platinum-sensitive recurrent diesase.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Abevmy (Biocon / Viatris) (November-2021)
Biosimilars Approved In The E.U.
Abevmy (Biocon / Viatris) (April-2021)
Biosimilars Approved In Australia
Abevmy (Alphapharm) (September-2021)
